Diagnosis and Treatment of Hyperthyroidism

  • Rosa Miranda Testa
  • Silvia Martinelli
  • Furio Pacini


This chapter deals with the current management of patients presenting with an excess of circulating thyroid hormones. This condition is known under two different words: hyperthyroidism and thyrotoxicosis describing two distinct pathologic conditions that should be recognized at diagnosis because they have a different natural history and may have different therapeutic approaches. The hypertiroidism indicates a condition determined by an excessive synthesis of thyroid hormones by the thyroid tissue, any cause. In the United States hyperthyroidism has a prevalence of approximately 1.2% of the population. The most common cause is Graves’ disease (GD), followed by toxic nodular goiter, whose prevalence increases with age, particularly in the regions of iodine deficiency, or single hyperfunctioning thyroid adenoma (Plummer’s adenoma) and, more rarely a TSH-producing pituitary adenoma. The thyrotoxicosis reflects any medical condition associated with high levels of thyroid hormones in the blood, secondary to destructive process of the thyroid or caused by improper intake of drugs or supplements containing thyroid hormones. In this manuscript the Authors report the main important condition of of hyperthyroidism and thyreotoxicosis, the current approaches for their diagnosis, and the options for the treatment of patients (medical treatments, radioisotopic treatment). The most important drugs used in the clinical practice are examined, and some clinical recommendations before particular treatments are reported.


Hypertiroidism Thyrotoxicosis Antithyroid drugs Thyroid diseases diagnosis and treatment 


  1. 1.
    Manji N, Carr-Smith JD, Boelaert K, Allahabadia A, Armitage M, Chatterjee VK, et al. Influences of age, gender, smoking and family history on autoimmune thyroid disease phenotype. J Clin Endocrinol Metab. 2006;91:4873–80.CrossRefPubMedGoogle Scholar
  2. 2.
    Brent GA. Clinical practice: Graves’ disease. N Engl J Med. 2008;358:2544–54.CrossRefGoogle Scholar
  3. 3.
    Shapiro LE, Sievert R, Ong L, Ocampo EL, Chance RA, Lee M, Nanna M, Ferrick K, Surks MI. Minimal cardiac effects in asymptomatic athyreotic patients chronically treated with thyrotropin-suppressive doses of L-thyroxine. J Clin Endocrinol Metab. 1997;82(8):2592–5.PubMedGoogle Scholar
  4. 4.
    Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, Izumi M. Differences and similarities in the diagnosis and treatment of Graves’ disease in Europe, Japan, and the United States. Thyroid. 1991;1(2):129–35.CrossRefPubMedGoogle Scholar
  5. 5.
    Cooper DS, Rivkees SA. Putting propylthiouracil in perspective. J Clin Endocrinol Metab. 2009;94:1881–2.CrossRefPubMedGoogle Scholar
  6. 6.
    Bahn RS, Burch HS, Cooper DS, et al. The role of propylthiouracil in the management of Graves’ disease in adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid. 2009;19:673–4.CrossRefPubMedGoogle Scholar
  7. 7.
    Neumann S, Eliseeva E, McCoy JG, Napolitano G, Giuliani C, Monaco F, et al. A new smallmolecule antagonist inhibits Graves’ disease antibody activation of the TSH receptor. J Clin Endocrinol Metab. 2011;96:548–54.CrossRefPubMedGoogle Scholar
  8. 8.
    Neumann S, Huang W, Eliseeva E, Titus S, Thomas CJ, Gershengorn MC. A small molecule inverse agonist for the human thyroid- stimulating hormone receptor. Endocrinology. 2010;151:3454–9.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Glinoer D. The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology. Endocr Rev. 1997;18:404–33.CrossRefPubMedGoogle Scholar
  10. 10.
    Goodwin TM, Montoro M, Mestman JH, Perkary AE, Hershman JM. The role of chorionic gonadotropin in transient hyperthyroidism of hyperemesis gravidarum. Trans Assoc Am Phys. 1991;104:233–7.PubMedGoogle Scholar
  11. 11.
    Glinoer D. The regulation of thyroid function during normal pregnancy: importance of the iodine nutrition status. Best Pract Res Clin Endocrinol Metab. 2004 Jun;18(2):133–52.CrossRefPubMedGoogle Scholar
  12. 12.
    Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD. Thyrotropin-secreting pituitary tumors. Endocr Rev. 1996;17:610–38.PubMedGoogle Scholar
  13. 13.
    Beck-Peccoz P, Persani L. Medical management of thyrotropinsecreting pituitary adenomas. Pituitary. 2002;5:83–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Cohen-Lehman J, Dahl P, Danzi S, Klein I. Effects of amiodarone therapy on thyroid function. Nat Rev Endocrinol. 2010;6:34–41.CrossRefPubMedGoogle Scholar
  15. 15.
    Bogazzi F, Tomisti L, Bartalena L, Aghini-Lombardi F, Martino E. Amiodarone and the thyroid: a 2012 update. J Endocrinol Investig. 2012;35:340–8. Scholar
  16. 16.
    Tanda ML, Piantanida E, Lai A, Liparulo G, Sassi L, Bogazzi F, Wiersinga WM, Braverman LE, Martino E, Bartalena L. Diagnosis and management of amiodarone-induced thyrotoxicosis: similarities and differences between North American and European thyroidologists. Clin Endocrinol. 2008;69(5):812–8.CrossRefGoogle Scholar
  17. 17.
    Cappelli C, Pirola I, Gandossi E, Formenti A, Agosti B, Castellano M. Ultrasound findings of subacute thyroiditis: a single institution retrospective review. Acta Radiol. 2014;55(4):429–33.CrossRefPubMedGoogle Scholar
  18. 18.
    Tokuda Y, Kasagi K, Iida Y, Yamamoto K, Hatabu H, Hidaka A, Konishi J, Ishii Y. Sonography of subacute thyroiditis: changes in the findings during the course of the disease. J Clin Ultrasound. 1990;18(1):21–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Fatourechi V, Aniszewski JP, Fatourechi GZE, Atkinson EJ, Jacobsen SJ. Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmsted County, Minnesota, study. J Clin Endocrinol Metab. 2003;88(5):2100–5.CrossRefPubMedGoogle Scholar
  20. 20.
    Muller AF, Drexhage HA, Berghout A. Postpartum thyroiditis and autoimmune thyroiditis in women of childbearing age: recent insights and consequences for antenatal and postnatal care. Endocr Rev. 2001;22:605–30.CrossRefPubMedGoogle Scholar
  21. 21.
    Iitaka M, Morgenthaler NG, Momotani N, Nagata A, Ishikawa N, Ito K, Katayama S, Ito K. Stimulation of thyroid-stimulating hormone (TSH) receptor antibody production following painless thyroiditis. Clin Endocrinol. 2004;60(1):49–53.CrossRefGoogle Scholar
  22. 22.
    Miyakawa M, Tsushima T, Onoda N, Etoh M, Isozaki O, Arai M, Shizume K, Demura H. Thyroid ultrasonography related to clinical and laboratory findings in patients with silent thyroiditis. J Endocrinol Investig. 1992;15(4):289–95.CrossRefGoogle Scholar
  23. 23.
    Nikolai TF, Coombs GJ, McKenzie AK, Miller RW, Weir GJ Jr. Treatment of lymphocytic thyroiditis with spontaneously resolving hyperthyroidism (silent thyroiditis). Arch Intern Med. 1982;142(13):2281–3.CrossRefPubMedGoogle Scholar
  24. 24.
    Nikolai TF, Coombs GJ, McKenzie AK. Lymphocytic thyroiditis with spontaneously resolving hyperthyroidism and subacute thyroiditis. Long-term follow-up. Arch Intern Med. 1981;141:1455–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Roth LM, Talerman A. The enigma of struma ovarii. Pathology. 2007;39:139–46.CrossRefPubMedGoogle Scholar
  26. 26.
    Yassa L, Sadow P, Marqusee E. Malignant struma ovarii. Nat Clin Pract Endocrinol Metab. 2008;4:469–72.CrossRefPubMedGoogle Scholar
  27. 27.
    Dardik RB, Dardik M, Westra W, et al. Malignant struma ovarii: two case reports and a review of the literature. Gynecol Oncol. 1999;73:447–51.CrossRefPubMedGoogle Scholar
  28. 28.
    Noal S, Joly F, Leblanc E. Management of gestational trophoblastic disease. Gynecol Obstet Fertil. 2010;38(3):193–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343–421.CrossRefPubMedGoogle Scholar
  30. 30.
    De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet. 2016;388(10047):906–18.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Pacini F, Pinchera A. Serum and tissue thyroglobulin measurement: clinical applications in thyroid disease. Biochimie. 1999;81(5):463–7. Review.CrossRefPubMedGoogle Scholar
  32. 32.
    Cooper DS. Antithyroid drugs. N Engl J Med. 2005;352(9):905–17.CrossRefPubMedGoogle Scholar
  33. 33.
    Baskin HJ, Cobin RH, Duick DS, Gharib H, Guttler RB, Kaplan MM. American Association of Clinical Endocrinologists medical guidelines for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract. 2002;8:457–69.CrossRefGoogle Scholar
  34. 34.
    Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell’Unto E, et al. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med. 1998;338:73–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Otsuka F, Noh JY, Chino T, Shimizu T, Mukasa K, Ito K, Ito K. Taniyama M Hepatotoxicity and cutaneous reactions after antithyroid drug administration. Clin Endocrinol. 2012;77(2):310–5.CrossRefGoogle Scholar
  36. 36.
    Mandel SJ, Cooper DS. The use of antithyroid drugs in pregnancy and lactation. J Clin Endocrinol Metab. 2001;86:2354–9.CrossRefPubMedGoogle Scholar
  37. 37.
    Andersen SL, Olsen J, Wu CS, Laurberg P. Severity of birth defects after propylthiouracil exposure in early pregnancy. Thyroid. 2014;24:1533–40.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Ventrella S, Klein I. Beta-adrenergic receptor blocking drugs in the management of hyperthyroidism. Endocrinologist. 1994;4:391–9.CrossRefGoogle Scholar
  39. 39.
    Tarantini B, Ciuoli C, Di Cairano G, Guarino E, Mazzucato P, Montanaro A, Burroni L, Vattimo AG, Pacini F. Effectiveness of radioiodine (131-I) as definitive therapy in patients with autoimmune and non-autoimmune hyperthyroidism. J Endocrinol Investig. 2006;29(7):594–8.CrossRefGoogle Scholar
  40. 40.
    Acharya SH, Avenell A, Philip S, Burr J, Bevan JS, Abraham P. Radioiodine therapy (RAI) for Graves’ disease (GD) and the effect on ophthalmopathy: a systematic review. Clin Endocrinol. 2008;69(6):943–50.CrossRefGoogle Scholar
  41. 41.
    Ross DS. Radioiodine therapy for hyperthyroidism. N Engl J Med. 2011;364(6):542–50.CrossRefPubMedGoogle Scholar
  42. 42.
    Erbil Y, Ozluk Y, Giriş M, Salmaslioglu A, Issever H, Barbaros U, Kapran Y, Ozarmağan S, Tezelman S. Effect of lugol solution on thyroid gland blood flow and microvessel density in the patients with Graves’ disease. J Clin Endocrinol Metab. 2007;92(6):2182–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Rosa Miranda Testa
    • 1
  • Silvia Martinelli
    • 1
  • Furio Pacini
    • 2
  1. 1.Department of EndocrinologyHumanitas GavazzeniBergamoItaly
  2. 2.Department of Medical, Surgical and Neurological SciencesUniversity of SienaSienaItaly

Personalised recommendations